Skip to content
Medical Health Aged Care

New clinical trial to compare the effectiveness of IV treatments for severe asthma in children

Monash University 2 mins read

A clinical trial to determine the best intravenous (IV) treatments for children with severe asthma will go ahead thanks to an almost $5 million Medical Research Future Fund grant.

 

The clinical trial – spearheaded by Professor Simon Craig, Adjunct Clinical Professor in the School of Clinical Sciences at Monash Health and paediatric emergency medicine physician at Monash Medical Centre – will provide clinicians with clear evidence to make more informed decisions, provide faster and more effective treatment, reduce unnecessary variation between hospitals, and ultimately improve outcomes for children with severe asthma.

 

“Asthma is one of the most common reasons children come to emergency departments across Australia. Most children improve with standard treatments such as inhaled salbutamol and oral steroids, but a small group remain very unwell and are at risk of needing intensive care. For these children, doctors often use ‘second-line’ medicines given through a vein to help open the airways,” Professor Craig said. 

 

“The two most commonly used options in Australia are IV magnesium and IV aminophylline; however, we don't know which one works better. Practice varies between hospitals, and decisions are often based on tradition rather than strong evidence. Because both medicines have potential benefits and risks, families and clinicians need clear evidence to guide decisions.” 

 

This randomised controlled trial will directly compare the two treatments in children who need extra help beyond standard care. 

The research team aims to compare the two treatments in over 1,000 children aged from two to 15 years with acute asthma, across 18 hospitals throughout Australia and New Zealand, all part of the PREDICT network. 

 

“By measuring how quickly children improve, how long they stay in hospital, how often they need admission to intensive care, and what side effects occur, the study will provide the first strong, head-to-head evidence about which medicine gives the best balance of benefit and safety,” Professor Craig said. 

 

MEDIA ENQUIRIES 

Helena Powell

Media Advisor (medical), Monash University 

M: +61 474 444 171

E: [email protected] 

 

GENERAL MEDIA ENQUIRIES

Monash Media

T: +61 (0) 3 9903 4840

E: [email protected]

For more Monash media stories, visit our news and events site

More from this category

  • Indigenous, Medical Health Aged Care
  • 18/03/2026
  • 07:21
Australian and New Zealand Journal of Public Health / Public Health Association of Australia

Emerging Aboriginal leaders call for greater Indigenous control over native foods

As Australia’s native food industry booms, experts say Indigenous people must have a seat at the table Aboriginal leaders and advocates have joined together today to call out commercial companies exploiting native food knowledge without adequate community engagement. They are urging government action to ensure Indigenous people can better lead and control the access and benefits that arise from their traditional foods and knowledge. The new evidence-based commentary, published in the Australian and New Zealand Journal of Public Health, represents the collective view of six leading Aboriginal academics and one non-Indigenous researcher with expertise across bush food, traditional Indigenous medicines,…

  • Medical Health Aged Care
  • 18/03/2026
  • 01:41
DNA Script

DNA Script Expands Global Access to On-demand DNA Synthesis With Distributor Agreements in Latin America and East Asia

Enables researchers worldwide to access high-quality ssDNA oligonucleotides within hours Establishes direct distribution networks across Latin America, Japan and South Korea PARIS–BUSINESS WIRE– DNA…

  • Contains:
  • Medical Health Aged Care
  • 18/03/2026
  • 01:21
Vectramind Health

Healthcare Technology Research Company, KLAS Research, Reports 100% of Surveyed Customers Would Buy Vectramind Health’s Firstpass Platform Again

Dubai, UAE— March 2026Vectramind Health today announced that its’ AI-native patient experience and engagement platform, Firstpass, has received strong validation in a newly released KLAS First Look report highlighting high levels of customer satisfaction and measurable improvements in patient engagement and operational efficiency. The findings, published in theKLAS Research report‘Vectramind Firstpass Unified Patient Experience & Engagement Platform 2026’, show that100% of surveyed customers said they would buy Firstpass again and consider the platform part of their long-term plans.Healthcare organizations also reported increased patient engagement, improved patient flow, reduced no-show rates, and reduced waiting times. The KLAS Research findings, which are…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.